BPC
UTHR icon

Bryce Point Capital’s United Therapeutics UTHR Stock Holding History

Bryce Point Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$572K Buy
+1,365
New +$459K 0.7% 55
2025
Q1 		– Sell
-3,522
Closed -$1.24M – 442
2024
Q4 		$1.24M Buy
+3,522
New +$1.29M 0.36% 113

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Bryce Point Capital's UTHR Position: Q3 2025 in Review

Bryce Point Capital opened a new position in United Therapeutics (UTHR) in Q3 2025: 1,365 shares worth $572K. The stake represents 0.7% of the portfolio and ranks #55 among its holdings. This is a return to the name: Bryce Point Capital previously reported a position in UTHR as recently as Q4 2024.

Bryce Point Capital first reported a position in UTHR in Q4 2024 and has held it in 2 quarters since. The position peaked at $1.24M in Q4 2024. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.

  • Bryce Point Capital held 1,365 shares of United Therapeutics worth $572K as of Q3 2025.
  • United Therapeutics was a new Bryce Point Capital position in Q3 2025.
  • United Therapeutics made up 0.7% of Bryce Point Capital's portfolio in Q3 2025, its #55 holding.
  • Bryce Point Capital first reported a position in United Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • Bryce Point Capital's United Therapeutics position peaked at $1.24M in Q4 2024.
  • 707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.